Electroacupuncture versus Escitalopram for mild to moderate Post-Stroke Depression: A randomized non-inferiority trial
ConclusionElectroacupuncture is an effective, alternative to escitalopram for the treatment of mild-to-moderate PSD.Clinical trial registrationChinese Clinical Trial Registry (ChiCTR2300072576). (Source: Frontiers in Psychiatry)
Source: Frontiers in Psychiatry - February 2, 2024 Category: Psychiatry Source Type: research
Machine Learning-Based Prediction of Escitalopram and Sertraline Side Effects with Pharmacokinetic Data in Children and Adolescents
This study evaluated data from 288 escitalopram-treated and 255 sertraline-treated patients ≤ 18 years old to develop machine learning models to predict side effects using electronic health record data and Bayesian estimated pharmacokinetic parameters. Trained on a combined cohort of escitalopram- and sertraline-treated patients, a penalized logistic regression model achieved an area under the receiver operating characteristic curve (AUROC) of 0.77 (95% confidence interval (CI): 0.66-0.88), with 0.69 sensitivity (95% CI: 0.54-0.86), and 0.82 specificity (95% CI: 0.72-0.87). Medication exposure, clearance, and time since ...
Source: Clinical Pharmacology and Therapeutics - February 1, 2024 Category: Drugs & Pharmacology Authors: Ethan A Poweleit Samuel E Vaughn Zeruesenay Desta Judith W Dexheimer Jeffrey R Strawn Laura B Ramsey Source Type: research
Pharmacokinetic correlates of clinical response in a naturalistic sample of escitalopram-treated patients
CONCLUSIONS: Patients with low clearance of escitalopram as reflected upon high C/D ratios may be less likely respond to escitalopram. Identifying these patients during dose titration may support clinical decision-making, including switching to a different antidepressant instead of increasing daily dose.PMID:38299560 | DOI:10.1080/17512433.2024.2314211 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - February 1, 2024 Category: Drugs & Pharmacology Authors: Nicholas Kasperk Ekkehard Haen Christoph Hiemke Thomas Frodl Georgios Schoretsanitis Michael Paulzen Nazar Kuzo Source Type: research
Inhibitory Actions of Antidepressants, Hypnotics, and Anxiolytics on Recombinant Human Acetylcholinesterase Activity
Biol Pharm Bull. 2024;47(1):328-333. doi: 10.1248/bpb.b23-00719.ABSTRACTAlzheimer's disease (AD) is accompanied by behavioral and psychological symptoms of dementia (BPSD), which is often alleviated by treatment with psychotropic drugs, such as antidepressants, hypnotics, and anxiolytics. If these drugs also inhibit acetylcholinesterase (AChE) activity, they may contribute to the suppression of AD progression by increasing brain acetylcholine concentrations. We tested the potential inhibitory effects of 31 antidepressants, 21 hypnotics, and 12 anxiolytics on recombinant human AChE (rhAChE) activity. At a concentration of 1...
Source: Biological and Pharmaceutical Bulletin - January 31, 2024 Category: Drugs & Pharmacology Authors: Keisuke Obara Haruka Mori Suzune Ihara Kento Yoshioka Yoshio Tanaka Source Type: research
Efficacy and safety of agomelatine in epilepsy patients with sleep and mood disorders: An observational, retrospective cohort study
Epilepsy Behav. 2024 Jan 28;152:109641. doi: 10.1016/j.yebeh.2024.109641. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate the therapeutic efficacy and safety of agomelatine for treating the sleep and mood disorders in epilepsy patients.METHODS: Retrospective data were derived from 113 epilepsy patients for at least 8 weeks. All the subjects were divided into two groups, one was treated with agomelatine, the other was treated with escitalopram. Their depression and anxiety states were assessed by Hamilton Depression (HAMD) and Hamilton Anxiety (HAMA) Scales. Sleep quality was assessed by the Pittsburgh Sleep Quality In...
Source: Epilepsy and Behaviour - January 29, 2024 Category: Neurology Authors: Jing Jiang Yu-Jiao Wu Cui-Hua Yan Yang Jin Ting-Ting Yang Tao Han Xue-Wu Liu Source Type: research
Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis
CONCLUSION: Escitalopram augmentation of antipsychotics appears to be the most efficacious treatment with moderate certainty of evidence among the available pharmacological interventions.PROSPERO REGISTRATION: CRD42022380292.PMID:38269529 | DOI:10.1080/17512433.2024.2310715 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - January 25, 2024 Category: Drugs & Pharmacology Authors: Archana Mishra Rituparna Maiti Biswa Ranjan Mishra Anand Srinivasan Source Type: research
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression
CONCLUSIONS: Overall, our results suggest that psychedelic therapy may be less vulnerable to expectancy biases than previously suspected. The relationship between baseline trait suggestibility and response to psilocybin therapy implies that highly suggestible individuals may be primed for response to this treatment.PMID:38247730 | DOI:10.1017/S0033291723003653 (Source: Psychological Medicine)
Source: Psychological Medicine - January 22, 2024 Category: Psychiatry Authors: Bal ázs Szigeti Brandon Weiss Fernando E Rosas David Erritzoe David Nutt Robin Carhart-Harris Source Type: research
Response to Pl öderl et al. re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”
Journal of Child and Adolescent Psychopharmacology, Ahead of Print. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - January 16, 2024 Category: Pediatrics Authors: Jeffrey R. Strawn Jeffrey A. Mills Source Type: research
Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals
ConclusionThe age-related increase in C/D ratio starts in middle-aged adults and progresses up to more than twofold higher C/D ratio in the oldest old. Sertraline seems to be less prone to age-related changes in C/D ratio than the other antidepressants. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 10, 2024 Category: Drugs & Pharmacology Source Type: research
Unraveling the potential of vitamins C and D as adjuvants in depression treatment with escitalopram in an LPS animal model
In conclusion, vitamins C and D enhance the therapeutic effects of escitalopram through a mechanism independent of Nrf2. These findings underscore the imperative need for in-depth investigations.PMID:38180676 | DOI:10.1007/s10787-023-01404-9 (Source: Cancer Control)
Source: Cancer Control - January 5, 2024 Category: Cancer & Oncology Authors: Omar Gammoh Rand T Akasheh Esam Qnais Sara Al-Taber Rabaa Y Athamneh Amin A Hafiz Abdelrahim Alqudah Alaa A A Aljabali Murtaza M Tambuwala Source Type: research
Unraveling the potential of vitamins C and D as adjuvants in depression treatment with escitalopram in an LPS animal model
In conclusion, vitamins C and D enhance the therapeutic effects of escitalopram through a mechanism independent of Nrf2. These findings underscore the imperative need for in-depth investigations. (Source: Inflammopharmacology)
Source: Inflammopharmacology - January 5, 2024 Category: Drugs & Pharmacology Source Type: research
Perinatal Depression: A Guide to Detection and Management in Primary Care
Conclusions:
These clinically relevant data can support the delivery of high-quality care by PCCs. Risks and benefits of PD treatments and the consequences of untreated PD should be discussed with patients to support informed decision making. (Source: Journal of the American Board of Family Medicine)
Source: Journal of the American Board of Family Medicine - January 5, 2024 Category: Primary Care Authors: Dama, M. H., Van Lieshout, R. J. Tags: Clinical Review Source Type: research
Comparative Efficacy of Augmenting Escitalopram with Modified Electroconvulsive Therapy or High-Frequency Repetitive Transcranial Magnetic Stimulation on Depressive Symptoms, Quality of Life, and Cognitive Function in Treatment-Resistant Depression
Tohoku J Exp Med. 2023 Dec 28. doi: 10.1620/tjem.2023.J103. Online ahead of print.NO ABSTRACTPMID:38171724 | DOI:10.1620/tjem.2023.J103 (Source: The Tohoku Journal of Experimental Medicine)
Source: The Tohoku Journal of Experimental Medicine - January 3, 2024 Category: Research Authors: Bo-Wen Yin Liu Yang Source Type: research
Comparative Efficacy of Augmenting Escitalopram with Modified Electroconvulsive Therapy or High-Frequency Repetitive Transcranial Magnetic Stimulation on Depressive Symptoms, Quality of Life, and Cognitive Function in Treatment-Resistant Depression
Tohoku J Exp Med. 2023 Dec 28. doi: 10.1620/tjem.2023.J103. Online ahead of print.NO ABSTRACTPMID:38171724 | DOI:10.1620/tjem.2023.J103 (Source: The Tohoku Journal of Experimental Medicine)
Source: The Tohoku Journal of Experimental Medicine - January 3, 2024 Category: Research Authors: Bo-Wen Yin Liu Yang Source Type: research
